New drug-eluting stents: technological refinement continues
The arrival of drug-eluting stents (DES) nearly 2 decades ago ignited a revolution Wine Cabinet in the field of interventional cardiology.The addition of antiproliferative drugs to the stent platform reduced the rate of in-stent restenosis significantly and increased the number of patients that, to this date, have benefited from percutaneous revasc